Veru (NASDAQ:VERU) Releases Earnings Results, Beats Estimates By $0.01 EPS

Veru (NASDAQ:VERU) issued its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%.

Veru Stock Up 3.0 %

Shares of NASDAQ:VERU traded up $0.02 on Friday, reaching $0.54. The company had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. Veru has a twelve month low of $0.40 and a twelve month high of $1.92. The stock has a market capitalization of $79.24 million, a P/E ratio of -1.93 and a beta of -0.54. The stock has a 50-day moving average price of $0.71 and a 200 day moving average price of $0.77.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VERU. Oppenheimer reiterated an “outperform” rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Veru in a research report on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.